Dr Maria Fragiadaki
Senior Lecturer
Translational Medicine and Therapeutics, The William Harvey Research Institute
Queen Mary University of London
Queen Mary University of London
Research
Kidney, Kidney-on-a-Chip, polycystic kidney disease, ADPKD, renal toxicity, drug screening
Interests
My lab is intrestrd in developing a kidney-on-chip (KoC) model for drug testing using patient-derived cells from Autosomal Dominant Polycystic Kidney Disease (ADPKD). This approach could significantly advance our understanding of ADPKD and accelerate drug discovery for this genetic disorder. By using patient-derived cells, you can create a more accurate representation of the disease microenvironment, allowing for better prediction of drug efficacy and toxicity. This model could be particularly valuable for testing novel therapies and for identifying potential biomarkers for ADPKD progression and treatment response.Publications
2023
Mullenger JL, Zeidler MP and Fragiadaki M (2023). Evaluating the Molecular Properties and Function of ANKHD1, and Its Role in Cancer. MDPI International Journal of Molecular Sciences vol. 24, (16) 2022
Souilhol C, Ayllon BT, Li X, Diagbouga MR, Zhou Z, Canham L, Roddie H, Pirri D, Chambers EV, Dunning MJ, Ariaans M, Li J, Fang Y, Jørgensen HF, Simons M, Krams R, Waltenberger J, Fragiadaki M, Ridger V, De Val S, Francis SE, Chico TJA, Serbanovic-Canic J and Evans PC (2022). JAG1-NOTCH4 mechanosensing drives atherosclerosis. American Association for the Advancement of Science Science Advances vol. 8, (35)